Select Publications
Journal articles
2021, 'Prospective associations of the original Food Standards Agency nutrient profiling system and three variants with weight gain, overweight and obesity risk: Results from the French NutriNet-Santé cohort', British Journal of Nutrition, 125, pp. 902 - 914, http://dx.doi.org/10.1017/S0007114520003384
,2021, 'Sodium, Blood Pressure, and the Likely Massive Avoidable Burden of Cardiovascular Disease', Circulation, 143, pp. 1568 - 1570, http://dx.doi.org/10.1161/CIRCULATIONAHA.120.052654
,2021, 'Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial', Cardiovascular Research, 118, pp. 1103 - 1114, http://dx.doi.org/10.1093/cvr/cvab128
,2021, 'Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis', The Lancet Oncology, 22, pp. 558 - 570, http://dx.doi.org/10.1016/S1470-2045(21)00033-4
,2021, 'Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program', ESC Heart Failure, 8, pp. 1482 - 1493, http://dx.doi.org/10.1002/ehf2.13236
,2021, 'Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice', Kidney International, 99, pp. 999 - 1009, http://dx.doi.org/10.1016/j.kint.2020.10.042
,2021, 'POS-223 Clinical Utility of KidneyIntelX in Patients with Early Stages of Diabetic Kidney Disease in CANVAS Participants', Kidney International Reports, 6, pp. s93 - s94, http://dx.doi.org/10.1016/j.ekir.2021.03.237
,2021, 'Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial', American Heart Journal, 233, pp. 141 - 148, http://dx.doi.org/10.1016/j.ahj.2020.12.008
,2021, 'An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials', International Journal of Cardiology, 324, pp. 165 - 172, http://dx.doi.org/10.1016/j.ijcard.2020.09.050
,2021, 'Sodium Reduction: How Big Might the Risks and Benefits Be?', Heart Lung and Circulation, 30, pp. 180 - 185, http://dx.doi.org/10.1016/j.hlc.2020.07.011
,2021, 'Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes', Diabetes, Obesity and Metabolism, 23, pp. 382 - 390, http://dx.doi.org/10.1111/dom.14226
,2021, 'Availability, healthiness, and price of packaged and unpackaged foods in India: A cross-sectional study', Nutrition and Health, 28, pp. 571 - 579, http://dx.doi.org/10.1177/02601060211039124
,2021, 'Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study', Diabetes Care, 44, pp. 210 - 216, http://dx.doi.org/10.2337/dc20-1889
,2021, 'Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis', Clinical Journal of the American Society of Nephrology, 16, pp. 384 - 395, http://dx.doi.org/10.2215/CJN.15260920
,2021, 'Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program', American Journal of Kidney Diseases, 77, pp. 23 - 34.e1, http://dx.doi.org/10.1053/j.ajkd.2020.06.018
,2021, 'Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis', Diabetes, Obesity and Metabolism, 23, pp. 252 - 257, http://dx.doi.org/10.1111/dom.14197
,2021, 'Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol', American Heart Journal, 231, pp. 56 - 67, http://dx.doi.org/10.1016/j.ahj.2020.09.017
,2021, 'Vital signs during the COVID-19 outbreak: A retrospective analysis of 19,960 participants in Wuhan and four nearby capital cities in China', Global Heart, 16, pp. 47, http://dx.doi.org/10.5334/GH.913
,2021, 'Availability, Formulation, Labeling, and Price of Low-sodium Salt Worldwide: Environmental Scan (Preprint)', JMIR Public Health and Surveillance, 7, http://dx.doi.org/10.2196/27423
,2021, 'Canagliflozin and Cardiovascular Outcomes in Patients With and Without Peripheral Artery Disease At Baseline: Data from the CANVAS Program and CREDENCE Trials', Heart Lung and Circulation, 30, pp. s215, http://dx.doi.org/10.1016/j.hlc.2021.06.263
,2021, 'Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population', Journal of the American Society of Nephrology, 32, pp. 47 - 47, http://dx.doi.org/10.1681/asn.20213210s147a
,2021, 'Corrigendum', ESC Heart Failure, 8, pp. 3447 - 3447, http://dx.doi.org/10.1002/ehf2.13408
,2021, 'Estimating the potential impact of Australia’s reformulation programme on households’ sodium purchases', BMJ Nutrition, Prevention & Health, 4, pp. 49 - 58, http://dx.doi.org/10.1136/bmjnph-2020-000173
,2021, 'KidneyIntelX as an Enrichment Tool for Clinical Trials in Early Diabetic Kidney Disease', Journal of the American Society of Nephrology, 32, pp. 263 - 263, http://dx.doi.org/10.1681/asn.20213210s1263a
,2020, 'Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study', Journal of the American College of Cardiology, 76, pp. 2982 - 3021, http://dx.doi.org/10.1016/j.jacc.2020.11.010
,2020, 'Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1705 - 1714, http://dx.doi.org/10.2215/CJN.10140620
,2020, 'Correction to: Contribution of major food companies and their products to household dietary sodium purchases in Australia (International Journal of Behavioral Nutrition and Physical Activity, (2020), 17, 1, (81), 10.1186/s12966-020-00982-z)', International Journal of Behavioral Nutrition and Physical Activity, 17, pp. 159, http://dx.doi.org/10.1186/s12966-020-01064-w
,2020, 'The impact of voluntary front-of-pack nutrition labelling on packaged food reformulation: A difference-in-differences analysis of the Australasian Health Star Rating scheme', PLoS Medicine, 17, pp. e1003427, http://dx.doi.org/10.1371/journal.pmed.1003427
,2020, 'Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction', Journal of the American College of Cardiology, 76, pp. 2076 - 2085, http://dx.doi.org/10.1016/j.jacc.2020.09.004
,2020, 'Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial', The Lancet Diabetes and Endocrinology, 8, pp. 903 - 914, http://dx.doi.org/10.1016/s2213-8587(20)30300-4
,2020, 'Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 2199 - 2203, http://dx.doi.org/10.1111/dom.14143
,2020, 'Seventeen-year associations between diet quality defined by the health star rating and mortality in australians: The australian diabetes, obesity and lifestyle study (ausdiab)', Current Developments in Nutrition, 4, pp. nzaa157 - nzaa157, http://dx.doi.org/10.1093/cdn/nzaa157
,2020, 'The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program', International Journal of Cardiology, 318, pp. 126 - 129, http://dx.doi.org/10.1016/j.ijcard.2020.06.011
,2020, 'Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program', Journal of the American Society of Nephrology, 31, pp. 2446 - 2456, http://dx.doi.org/10.1681/ASN.2019121312
,2020, 'Estimated 24-Hour Urinary Sodium Excretion and Incident Cardiovascular Disease and Mortality among 398628 Individuals in UK Biobank', Hypertension, 76, pp. 683 - 691, http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.14302
,2020, 'Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes', Kidney International, 98, pp. 769 - 777, http://dx.doi.org/10.1016/j.kint.2020.04.051
,2020, 'Prospective associations of four nutrient profiles with weigh gain, overweight and obesity risk', European Journal of Public Health, 30, pp. ckaa166.1285 - V1009, http://dx.doi.org/10.1093/eurpub/ckaa166.1285
,2020, 'Impact of salt substitute and stepwise reduction of salt supply on blood pressure in residents in senior residential facilities: Design and rationale of the DECIDE-Salt trial', American Heart Journal, 226, pp. 198 - 205, http://dx.doi.org/10.1016/j.ahj.2020.05.013
,2020, 'Rationale, design, and baseline characteristics of the Salt Substitute in India Study (SSiIS): The protocol for a double-blinded, randomized-controlled trial', Journal of Clinical Hypertension, 22, pp. 1504 - 1512, http://dx.doi.org/10.1111/jch.13947
,2020, 'The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis', Progress in Cardiovascular Diseases, 63, pp. 518 - 524, http://dx.doi.org/10.1016/j.pcad.2020.04.008
,2020, 'Effects of allopurinol on the progression of chronic kidney disease', New England Journal of Medicine, 382, pp. 2504 - 2513, http://dx.doi.org/10.1056/NEJMoa1915833
,2020, 'Contribution of major food companies and their products to household dietary sodium purchases in Australia', International Journal of Behavioral Nutrition and Physical Activity, 17, pp. 81, http://dx.doi.org/10.1186/s12966-020-00982-z
,2020, '27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease', Diabetes, 69, http://dx.doi.org/10.2337/db20-27-or
,2020, 'Is salt substitution ready for prime time?', Nature Reviews Cardiology, 17, pp. 325 - 326, http://dx.doi.org/10.1038/s41569-020-0365-0
,2020, 'P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1013, http://dx.doi.org/10.1093/ndt/gfaa142.p1013
,2020, 'P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa142.p1019
,2020, 'The effects of a supermarket-based intervention on the nutritional quality of private-label foods: A prospective study', Nutrients, 12, pp. 1 - 16, http://dx.doi.org/10.3390/nu12061692
,2020, 'Uptake of australia’s health star rating system 2014–2019', Nutrients, 12, pp. 1 - 13, http://dx.doi.org/10.3390/nu12061791
,2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, 22, pp. 1753 - 1766, http://dx.doi.org/10.1111/dom.14091
,2020, 'A Systematic Review of the Sources of Dietary Salt Around the World', Advances in Nutrition, 11, pp. 677 - 686, http://dx.doi.org/10.1093/advances/nmz134
,